Duato
J&J’s Swift $14.6B Acquisition of Intra-Cellular Therapies: A CEO-Driven Deal
Johnson & Johnson, Intra-Cellular Therapies, acquisition, neuroscience, CAPLYTA, Joaquin Duato, pharmaceutical industry, M&A
Actionable Insights Powered by AI
Johnson & Johnson, Intra-Cellular Therapies, acquisition, neuroscience, CAPLYTA, Joaquin Duato, pharmaceutical industry, M&A